Literature DB >> 16198418

mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.

P B Staber1, C Noehammer, H Dürkop, S Schauer, L Kenner, W Linkesch, G Hoefler.   

Abstract

One of the main functions of the tumor necrosis factor receptor (TNFR) family is induction of apoptosis. CD30, a member of the TNFR superfamily is overexpressed in highly proliferating tumors such as anaplastic large cell lymphoma (ALCL) and Hodgkin's lymphoma (HL). CD30 stimulation leads to apoptosis and growth arrest in cultured ALCL, but not in Hodgkin-Reed-Sternberg cells. To identify changes in the transcriptional program responsible for these opposing effects, we performed gene expression analysis in CD30-stimulated ALCL (Karpas 299) and HL (KM-H2) cell lines using cDNA microarrays. Selected genes were validated by real-time PCR. Hierarchical clustering was applied to the whole dataset and separated the cell lines clearly with respect to their origin. In HL, there were only minor CD30-specific alterations, whereas ALCL unequivocally showed a pronounced CD30-specific transcriptional response. Ninety-three genes (6.6% of total) were deregulated by more than a factor of two after CD30 stimulation in ALCL cells. The majority of genes identified are involved in cell cycle regulation and apoptosis. mRNA expression patterns further indicate that in contrast to HL, CD30 stimulation in ALCL induces cell death via the CD95-CD95 ligand (CD95L) pathway and the TNF-R1/TNF-R2 crosstalk. These data provide a detailed view on the transcriptional changes upon CD30 stimulation and may explain the observed functional differences of HL and ALCL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16198418     DOI: 10.1016/j.leukres.2005.08.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  6 in total

1.  Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.

Authors:  Eva Geissinger; Petra Sadler; Sabine Roth; Tina Grieb; Bernhard Puppe; Nora Müller; Peter Reimer; Claudia S Vetter-Kauczok; Jörg Wenzel; Irina Bonzheim; Thomas Rüdiger; Hans Konrad Müller-Hermelink; Andreas Rosenwald
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

2.  Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines.

Authors:  Moo Rim Kang; Jong Soon Kang; Jeong Wook Yang; Bo Geun Kim; Jin-Ah Kim; Yeong Nang Jo; Kiho Lee; Chang Woo Lee; Ki Hoon Lee; Jieun Yun; Hwan Mook Kim; Gyoonhee Han; Jong Seong Kang; Song-Kyu Park
Journal:  Oncol Lett       Date:  2011-09-28       Impact factor: 2.967

3.  Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.

Authors:  Peng Zhang; Nianxi Zhao; Zihua Zeng; Yongdong Feng; Ching-Hsuan Tung; Chung-Che Chang; Youli Zu
Journal:  Lab Invest       Date:  2009-10-12       Impact factor: 5.662

4.  CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.

Authors:  Burkhard Hirsch; Michael Hummel; Stefan Bentink; Fariba Fouladi; Rainer Spang; Raphael Zollinger; Harald Stein; Horst Dürkop
Journal:  Am J Pathol       Date:  2008-01-10       Impact factor: 4.307

5.  The Kaposi's sarcoma-associated herpesvirus viral interleukin 6 gene affects metastasis and expression of B cell markers in a murine xenograft model.

Authors:  R Amy Fullwood; Gregory M Low; Emily P Chase; Meagan Grasley; Soren S Beal; Ian M McCrary; Christian W Daniels; Kayleigh Ingersoll; Bradford K Berges
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

Review 6.  Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions.

Authors:  C A van der Weyden; S A Pileri; A L Feldman; J Whisstock; H M Prince
Journal:  Blood Cancer J       Date:  2017-09-08       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.